Skip to main content
. 2021 Jul 28;2021:9980410. doi: 10.1155/2021/9980410

Table 1.

Clinicopathological features related to the TCGA subtypes.

Variable N (%) EBV+ (n = 6) MSI (n = 13) GS (n = 28) CIN (n = 50) P value
Gender 0.094
 -Male 59 (60.8%) 6 (100) 7 (53.8) 16 (57.1) 30 (60)
 -Female 38 (39.2%) 0 (0) 6 (46.2) 12 (42.9) 20 (40)
Mean age at diagnosis (range) 59 (28-85) 61 (46-77) 59 (36-85) 56 (28-76) 62 (39-82) 0.275
Age at diagnosis 0.424
 -≥50 years 80 (82.5) 5 (83.3) 9 (69.2) 22 (78.6) 44 (88)
 -<50 years 17 (17.5) 1 (16.7) 4 (30.8) 6 (21.4) 6 (12)
History of gastrectomy 0.374
 -Yes 7 (7.2) 1 (16.7) 0 (0) 3 (10.7) 3 (6)
 -No 90 (92.8) 5 (83.3) 13 (100) 25 (89.3) 47 (94)
History of gastric ulcer 0.025
 -Yes 3 (3.1) 2 (33.3) 0 (0) 0 (0) 1 (2)
 -No 94 (96.9) 4 (66.7) 13 (100) 28 (100) 49 (98)
Tobacco smoking 0.161
 -Yes 25 (25.8) 3 (50) 1 (7.7) 6 (21.4) 15 (30)
 -No 72 (74.2) 3 (50) 12 (92.3) 22 (78.6) 35 (70)
Tumor location 0.789
 -Cardia 31 (31.9) 2 (33.3) 4 (30.8) 11 (39.3) 14 (28)
 -Noncardia 66 (68.1) 4 (66.7) 9 (69.2) 17 (60.7) 36 (72)
Tumor cells differentiation 0.081
 -Well/moderate 62 (63.9) 2 (33.3) 7 (53.8) 15 (53.6) 38 (76)
 -Poor 35 (36.1) 4 (66.7) 6 (46.2) 13 (46.4) 12 (24)
Lauren classification 0.001
 -Intestinal 65 (67.1) 3 (50) 11 (84.6) 11 (39.3) 40 (80)
 -Diffuse/mixed 32 (32.9) 3 (50) 2 (15.4) 17 (60.7) 10 (20)
HER2 immunostaining 0.906
 -Positive 9 (9.3) 1 (16.7) 1 (7.7) 2 (7.1) 5 (10)
 -Negative 88 (90.7) 5 (83.3) 12 (92.3) 26 (92.9) 45 (90)
p53 immunostaining 0.134
 -Aberrant 49 (50.5) 2 (33.3) 5 (38.5) 11 (39.3) 31 (62)
 -Normal 48 (49.5) 4 (66.7) 8 (61.5) 17 (60.7) 19 (38)
PD-L1 immunostaining n = 38 n = 3 n = 6 n = 10 n = 19 0.177
 -Positive 6 (15.8) 1 (33.3) 3 (50) 0 (0) 2 (10.5)
 -Negative 32 (84.2) 2 (66.7) 3 (50) 10 (100) 17 (89.5)

TCGA: The Cancer Genome Atlas; EBV: Epstein-Barr virus; MSI: microsatellite instability; GS: genome stable; CIN: chromosomal instability; previously reported [13].